New combo therapy aims to outsmart tough leukemia
NCT ID NCT04560322
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of three drugs (venetoclax, obinutuzumab, and acalabrutinib) in 40 people with relapsed or refractory CLL or SLL. The treatment is adjusted based on how well the cancer responds (measured by minimal residual disease). The main goal is to see if at least 90% of participants are alive after one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
venetoclax, obinutuzumab, and acalabrutinib
What this could lead to
If successful, this could offer a more personalized treatment approach for people with hard-to-treat CLL or SLL, potentially improving survival and reducing the need for further therapy.
What could go wrong
This is a small, early-phase trial (40 people) with no control group, so results may not apply broadly. The drugs can cause serious side effects like infections or low blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
NOT_YET_RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Dana-Farber Cancer Institute
NOT_YET_RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Massachusetts General Hospital Cancer Center
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact